UY32450A - Variantes de unión a anti-albúmina de suero mejoradas - Google Patents

Variantes de unión a anti-albúmina de suero mejoradas

Info

Publication number
UY32450A
UY32450A UY0001032450A UY32450A UY32450A UY 32450 A UY32450 A UY 32450A UY 0001032450 A UY0001032450 A UY 0001032450A UY 32450 A UY32450 A UY 32450A UY 32450 A UY32450 A UY 32450A
Authority
UY
Uruguay
Prior art keywords
improved
serum anti
albumin variants
variants
albumin
Prior art date
Application number
UY0001032450A
Other languages
English (en)
Inventor
Elena De Angelis
Enever Carolyn
Liu Haiqun
Schon Oliver
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of UY32450A publication Critical patent/UY32450A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a variantes mejoradas del dominio variable sencillo de inmunoglobulina anti-albúmina de suero DOM7h-11, así como a ligandos y conjugados de fármacos que comprenden dichas variantes, composiciones, ácido nucleicos, vectores y huéspedes.
UY0001032450A 2009-02-19 2010-02-17 Variantes de unión a anti-albúmina de suero mejoradas UY32450A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15374609P 2009-02-19 2009-02-19
US16398709P 2009-03-27 2009-03-27
US24713609P 2009-09-30 2009-09-30

Publications (1)

Publication Number Publication Date
UY32450A true UY32450A (es) 2010-09-30

Family

ID=42634270

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032450A UY32450A (es) 2009-02-19 2010-02-17 Variantes de unión a anti-albúmina de suero mejoradas

Country Status (25)

Country Link
US (3) US9534043B2 (es)
EP (3) EP3656788A3 (es)
JP (2) JP5759391B2 (es)
KR (1) KR101819754B1 (es)
CN (1) CN102405233B (es)
AR (1) AR075505A1 (es)
AU (1) AU2010215482B2 (es)
BR (1) BRPI1013341B1 (es)
CA (2) CA2767752C (es)
CL (1) CL2011002025A1 (es)
CO (1) CO6410311A2 (es)
DO (1) DOP2011000266A (es)
EA (1) EA028178B1 (es)
ES (2) ES2774192T3 (es)
HK (1) HK1247944A1 (es)
IL (1) IL214480A0 (es)
MA (1) MA33051B1 (es)
MX (1) MX2011008749A (es)
NZ (1) NZ595242A (es)
PE (1) PE20120001A1 (es)
SG (1) SG173489A1 (es)
TW (1) TW201042039A (es)
UY (1) UY32450A (es)
WO (1) WO2010094723A2 (es)
ZA (1) ZA201105657B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2411054A2 (en) * 2009-03-27 2012-02-01 Glaxo Group Limited Drug fusions and conjugates
WO2011008814A2 (en) 2009-07-14 2011-01-20 Immune Tolerance Institute, Inc., A California Not-For-Profit Corporation Multiplexed measurement of exogenous and endogenous dna
MX2012003939A (es) * 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
MX2012005024A (es) * 2009-10-27 2012-09-07 Glaxo Group Ltd Polipeptidos anti-tnfr1 estables, dominios variables de anticuerpos y antagonistas.
BR112012029280A2 (pt) * 2010-05-20 2016-11-29 Glaxo Group Ltd variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão
EP2603522A1 (en) * 2010-08-13 2013-06-19 GlaxoSmithKline Intellectual Property Development Limited Improved anti-serum albumin binding variants
JP2014501725A (ja) * 2010-11-24 2014-01-23 グラクソ グループ リミテッド Ｈｇｆを標的とする多特異的抗原結合タンパク質
JP2014501515A (ja) 2010-12-01 2014-01-23 グラクソ グループ リミテッド 改良された抗血清アルブミン結合単一可変ドメイン
JP2014505698A (ja) 2011-02-02 2014-03-06 グラクソ グループ リミテッド 新規抗原結合タンパク質
CA3024500A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
WO2018224439A1 (en) * 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-hsa antibodies
IL271127B2 (en) 2017-06-05 2024-10-01 Numab Therapeutics AG New anti-HSA antibodies
WO2024170756A1 (en) 2023-02-17 2024-08-22 Ablynx N.V. Polypeptides binding to the neonatal fc receptor

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
EP2172553A1 (en) 2004-03-24 2010-04-07 Domantis Limited Gas1 universal leader
EA012622B1 (ru) 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
CN101128487B (zh) 2004-12-02 2012-10-10 杜门蒂斯有限公司 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体
CN101426815A (zh) * 2005-12-06 2009-05-06 杜门蒂斯有限公司 具有表皮生长因子受体和/或血管内皮生长因子结合特异性的配体及其使用方法
AU2007209201A1 (en) 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
GB0621513D0 (en) 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
EA200901494A1 (ru) 2007-06-06 2010-06-30 Домантис Лимитед Способы селекции протеазоустойчивых полипептидов
JP2012509658A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド Ｉｌ−１３に結合するリガンド
CN102405232B (zh) 2009-02-19 2015-08-19 葛兰素集团有限公司 改良的抗血清清蛋白结合变体
JP2012517818A (ja) * 2009-02-19 2012-08-09 グラクソ グループ リミテッド 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト
US20120107330A1 (en) * 2009-07-16 2012-05-03 Adriaan Allart Stoop Antagonists, uses & methods for partially inhibiting tnfr1
MX2012003939A (es) * 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
CA2796932A1 (en) * 2010-04-21 2011-10-27 Glaxo Group Limited Binding domains

Also Published As

Publication number Publication date
IL214480A0 (en) 2011-09-27
JP2015204831A (ja) 2015-11-19
JP5759391B2 (ja) 2015-08-05
JP6100315B2 (ja) 2017-03-22
CA3079184A1 (en) 2010-08-26
SG173489A1 (en) 2011-09-29
ES2655071T3 (es) 2018-02-16
NZ595242A (en) 2013-11-29
US9534043B2 (en) 2017-01-03
AU2010215482A1 (en) 2011-08-25
AR075505A1 (es) 2011-04-06
KR20110127223A (ko) 2011-11-24
EP3330287B1 (en) 2019-12-18
EP2398826B1 (en) 2017-10-25
ES2774192T3 (es) 2020-07-17
TW201042039A (en) 2010-12-01
US10696738B2 (en) 2020-06-30
WO2010094723A3 (en) 2011-04-21
CN102405233B (zh) 2014-11-26
JP2012517820A (ja) 2012-08-09
EP2398826A2 (en) 2011-12-28
HK1247944A1 (zh) 2018-10-05
US20110305696A1 (en) 2011-12-15
BRPI1013341A2 (pt) 2016-10-11
PE20120001A1 (es) 2012-02-12
KR101819754B1 (ko) 2018-01-18
CO6410311A2 (es) 2012-03-30
US20170298121A1 (en) 2017-10-19
BRPI1013341B1 (pt) 2021-09-08
DOP2011000266A (es) 2011-12-31
ZA201105657B (en) 2012-04-25
US20200283512A1 (en) 2020-09-10
MX2011008749A (es) 2011-09-06
EA201171068A1 (ru) 2012-02-28
EP3330287A1 (en) 2018-06-06
WO2010094723A2 (en) 2010-08-26
EA028178B1 (ru) 2017-10-31
AU2010215482B2 (en) 2014-02-13
CN102405233A (zh) 2012-04-04
MA33051B1 (fr) 2012-02-01
CA2767752A1 (en) 2010-08-26
EP3656788A3 (en) 2020-07-29
CA2767752C (en) 2020-07-07
EP3656788A2 (en) 2020-05-27
CL2011002025A1 (es) 2012-04-09

Similar Documents

Publication Publication Date Title
CO6450689A2 (es) Variantes de unión a anti-albúmina de suero mejoradas
UY32450A (es) Variantes de unión a anti-albúmina de suero mejoradas
IN2012DN00640A (es)
EA201401254A1 (ru) Самостабилизирующиеся линкерные конъюгаты
EA201992456A3 (ru) Самостабилизирующиеся линкерные конъюгаты
CY1119567T1 (el) Θεραπευτικα πεπτιδια
EA201291009A1 (ru) Улучшенные связывающие варианты против сывороточного альбумина
EA201171325A1 (ru) Нуклеиновые кислоты, связывающиеся с гепсидином
EA201200617A1 (ru) Полимеры на основе циклодекстрина для доставки лекарственных средств
CR20130266A (es) PROTEÍNAS DE UNIÓN AL TNF-a
EA201390785A1 (ru) Антитела, обладающие низкой аффинностью к рецепторам гематоэнцефалического барьера, и их применения
MX2017008215A (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
EA201101165A1 (ru) СОЕДИНЕНИЯ, МОДУЛИРУЮЩИЕ АКТИВНОСТЬ Toll-ПОДОБНЫХ РЕЦЕПТОРОВ
ECSP18062538A (es) Conjugado de enzimas terapéuticas
WO2011123820A3 (en) Single isomeric conjugates of rhodamine dyes
MA34025B1 (fr) Polypeptides se liant au bêta-a
BR112012001814A2 (pt) conjugados de proteína de coagulação sanguínea
EA201291065A1 (ru) Антитела против vla-4
TR201903403T4 (tr) İmmünoglobulin preparatı.
WO2012072731A3 (en) Improved anti-serum albumin binding single variable domains
EA201390116A1 (ru) Улучшенные связывающие варианты против сывороточного альбумина
LT2013016A (lt) Aktyvuotos-potencijuotos formos antikūno poveikio padidinimo būdas
CR20110473A (es) Variantes de union a anti-albúmina de suero mejoradas.
ITTO20080027A1 (it) Forma troncata della proteina p17 di hiv.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181218